The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics

Abstract

The evolution of chemistries and instrument platforms for next‐generation sequencing has led to sequencing of genomic variants in both tumor biopsies as well as in circulating tumor cells (CTCs) and cell‐free DNA liquid biopsies. The transition of these analytical platforms into clinical ones has led to challenges in product development as well as regulatory strategies for the approval of diagnostic products with these platforms. Regulatory strategies for liquid biopsy diagnostics depend on a framework that has been developed over the past few years by the US Food and Drug Administration (FDA). This framework includes both guidances that cover enrichment biomarkers and companion diagnostics, as well as regulatory approval precedents, which can be used to design regulatory strategies for new liquid biopsy diagnostic products. However, the regulatory paths for these liquid biopsy diagnostics can also be tortuous, as is the example of CTC—platform liquid biopsies. The ultimate success of regulatory pathways of liquid biopsy diagnostics has been driven by the incremental value of FDA approval for Clinical Laboratory Improvement Amendment (CLIA)‐developed tests and by the inherent complexity of these diagnostics, which are practical barriers for the widespread replication of these tests throughout CLIA laboratories. The framework for FDA approval of sequence information from these liquid biopsies has been focused on single‐site approvals of diagnostics where sequencing information is considered at different diagnostic risk levels, ranging from novel or follow‐on companion diagnostics to variant calls in genomic targets considered independently valuable for therapeutic decision making.

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

“…Overall, the goals for in vitro diagnostic biomarker studies are that they should produce valid scientific evidence demonstrating reasonable assurance of the safety and effectiveness of the product and protect the rights and welfare of study subjects. ( 63,64 )…”

Blood-Based Liquid Biopsies: A Noninvasive and Cost-Effective Tool for Improved Risk Assessment and Identification of Lymph Node Metastasis in Patients With Submucosal T1 Colorectal Cancer

“…Many biomarker panels have gone through such rigorous interrogations (eg, ColoGuard), which led to approvals by the US Food and Drug Administration for specific clinical applications. 8 In this issue of the Gastroenterology, Wada et al, 9 describe the process through which they developed a transcriptomic signature that consisted of both mRNA and microRNAs (miRNAs) for the identification of patients with T1 CRCs and presence of lymph nodes metastasis (LNM). This has potential eventual clinical application for helping to reduce overtreatment in those who are deemed to be lymph node negative.…”

Liquid biopsies in urological cancers: what we need to know before starting using them

“…However, the pre-analytical variability of the liquids, the differences of the sequencing chemistries and the innate methodological characteristics of NGS (variable library preparation, different software of variant calling) make difficult to homogenize the procedures in different laboratories. On clinical grounds, there are still no shared guidelines, except for EGFR mutations in lung cancer, for the timing of sampling and the biomarkers that must be investigated in each tumor type [27]. Genito-urinary malignancies may benefit from the implementation of liquid biopsies based on urine samples.…”